Latest Information Update: 27 Dec 2007
At a glance
- Originator Tularik
- Mechanism of Action Sodium channel agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 12 Jul 2001 Preclinical development for Thrombosis in USA (Unknown route)
- 20 Jul 2000 Protherics has licensed PMD 3112 to Eli Lilly in the USA
- 14 Mar 2000 New profile